Sub menu

Vaccines

MenQuadfi

Details for MenQuadfi (MenACWY-TT) vaccine and its components.

Recently added

This page was added on 16 December 2022.

Updates made

This page was updated on [date-counter-updated-date]. View history of updates

Sponsor
Sanofi Pasteur Pty Ltd
Administration route
Intramuscular injection
Vaccine group
Quadrivalent meningococcal conjugate vaccines
Description:

Registered for use in people aged ≥12 months

MenACWY-TT – quadrivalent meningococcal (serogroups A, C, W, Y)-tetanus toxoid conjugate vaccine

Clear, colourless, sterile, preservative-free solution

Each 0.5 mL dose of vaccine contains:

  • 10 µg meningococcal polysaccharide serogroup A
  • 10 µg meningococcal polysaccharide serogroup C
  • 10 µg meningococcal polysaccharide serogroup W
  • 10 µg meningococcal polysaccharide serogroup Y
  • Each of the four polysaccharides is conjugated to tetanus toxoid (approximately 55 µg/dose)

For Product Information and Consumer Medicine Information about MenQuadfi visit the Therapeutic Goods Administration website.

Related diseases
Meningococcal disease

Page history

Last updated
Last reviewed

Help us improve the Australian Immunisation Handbook

Printed content may be out of date. For up to date information, always refer to the digital version:

https://immunisationhandbook.health.gov.au/vaccines/menquadfi

All vaccines

Link copied

Link, share or bookmark directly to this section of the page.